Drugs / RUPITASERTIB
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01971515 | Dec 2013 → Aug 2018 | cancer | EMD Serono | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RUPITASERTIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4871106 ↗ |
| Known as | M-2698 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4871106 ↗ |
| Known as | MSC2363318A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01971515 ↗ |
| Action | Inhibit | “Serine/threonine-protein kinase AKT3 inhibitor” CHEMBL4871106 ↗1“Serine/threonine-protein kinase AKT inhibitor” CHEMBL4871106 ↗ |
| Modality | Small molecule | — CHEMBL4871106 ↗ |
| Route | Oral | “MSC2363318A will be administered orally once daily” NCT01971515 ↗ |
| Target | AKT1 | “Serine/threonine-protein kinase AKT inhibitor” CHEMBL4871106 ↗ |
| Target | AKT3 | “Serine/threonine-protein kinase AKT3 inhibitor” CHEMBL4871106 ↗ |